Citizens Financial Group Inc. RI Has $48.06 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Citizens Financial Group Inc. RI increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 34.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,087 shares of the company’s stock after purchasing an additional 13,488 shares during the period. Eli Lilly and Company makes up about 1.1% of Citizens Financial Group Inc. RI’s holdings, making the stock its 18th biggest position. Citizens Financial Group Inc. RI’s holdings in Eli Lilly and Company were worth $48,064,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in LLY. Tidemark LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $29,000. Core Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory acquired a new position in Eli Lilly and Company during the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company during the 2nd quarter valued at about $36,000. Finally, Frank Rimerman Advisors LLC bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $37,000. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on LLY shares. Barclays raised their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Bank of America upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 9th. Finally, Citigroup started coverage on shares of Eli Lilly and Company in a research report on Friday. They set a “buy” rating and a $1,060.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $977.35.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 17,229 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the sale, the insider now owns 97,556,910 shares of the company’s stock, valued at approximately $88,033,404,445.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 451,900 shares of company stock worth $418,732,178. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Down 1.2 %

Shares of LLY opened at $923.71 on Monday. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The business has a 50-day moving average of $897.12 and a 200 day moving average of $833.89. The firm has a market cap of $877.92 billion, a P/E ratio of 136.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.